SCHEMBL7177478

SCHEMBL7177478

CC(=O)C=Cc1cccc(O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 5/20 1.00
LMNA P02545 1/20 0.72
MAPT P10636 1/20 0.72
ERN1 O75460 1/20 0.59
BACE1 P56817 1/20 0.55
KDM4E B2RXH2 1/20 0.51
NFKB1 P19838 2/20 0.50
ALOX5 P09917 1/20 0.50
JUN P05412 1/20 0.50
NFE2L2 Q16236 1/20 0.50
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
RELA Q04206 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
GLA P06280 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26046362 1.00 IAPP (1.00) IAPPLMNAMAPTERN1BACE1
SCHEMBL29428452 0.84 MAPT (1.00) IAPPLMNAMAPTKDM4ENFKB1
SCHEMBL1404929 0.84 MAPT (1.00) IAPPLMNAMAPTKDM4ENFKB1
SCHEMBL1404928 0.84 MAPT (1.00) IAPPLMNAMAPTKDM4ENFKB1
SCHEMBL29377511 0.84 MAPT (1.00) IAPPLMNAMAPTKDM4ENFKB1
SCHEMBL1404990 0.83 IAPP (0.71) IAPPLMNAMAPTBACE1KDM4E
SCHEMBL1404989 0.83 IAPP (0.71) IAPPLMNAMAPTBACE1KDM4E
SCHEMBL307296 0.82 NFKB1 (0.71) IAPPLMNAMAPTERN1BACE1
SCHEMBL31083592 0.82 NFKB1 (0.71) IAPPLMNAMAPTERN1BACE1
SCHEMBL31256670 0.82 NFKB1 (0.71) IAPPLMNAMAPTERN1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200129450-A1 COMPOSITION COMPRISING OSMUNDACETONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING BONE DISEASE KORPHARM CO LTD (KR) 2020-04-30 US disclosed
EP-0726074-B1 METHOD FOR OBTAINING APOLAR AND POLAR EXTRACTS OF CURCUMA AND APPLICATIONS THEREOF A C PHARMACEUTICAL INTERNATION (ES) 2003-06-25 EP disclosed
US-6440468-B1 SUBJECTING POWDERED CURCUMA LONGA RHIZOMES TO SOLVENT EXTRACTION TO OBTAIN APOLAR EXTRACT, EXTRACTING WITH WATER TO OBTAIN POLAR EXTRACT, MIXING EXTRACTS A.S.A.C. PHARMACEUTICAL INTERNATIONAL, A.I.E. (ES) 2002-08-27 US disclosed
EP-0726074-A1 METHOD FOR OBTAINING APOLAR AND POLAR EXTRACTS OF CURCUMA AND APPLICATIONS THEREOF A.S.A.C. PHARMACEUTICAL INTERNATIONAL, A.I.E. (ES) 1996-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129450-A1 COMPOSITION COMPRISING OSMUNDACETONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING BONE DISEASE SOST, SLC10A6, OSTC IAPP 2006/4885LMNA 3786/4885MAPT 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.